Table 2. Characterization of nasal Staphylococcus aureus isolates (n = 123).
| CC | ST | spa types (n) | MRSA [n(%)] | MDR [n(%)] | PVL [n(%)] | TSST [n(%)] |
|---|---|---|---|---|---|---|
| CC1 | ST1 | t127 (3), t591 (1) | 0 (0.0) | 0 (0.0) | 2 (66.7) | 2 (66.7) |
| ST72 | t537 (2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (50.0) | |
| CC121 | ST121 | t311 (9), t314 (7), t645 (1), t1114 (2) | 0 (0.0) | 3 (15.8) | 13 (68.4) | 2 (10.5) |
| CC15 | ST15 | t84 (18), t085 (1), t346 (1), t385 (1) | 0 (0.0) | 2 (9.5) | 14 (66.7) | 3 (14.3) |
| CC152 | ST152 | t1096 (3), t355 (25), t1123 (2), t1172 (1), t1299 (4) | 1 (2.9) | 7 (20.0) | 30 (85.7) | 3 (8.6) |
| ST377 | t5047 (1) | 0 (0.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | |
| CC30 | ST30 | t318 (1), t363 (3), t2147 (1) | 0 (0.0) | 0 (0.0) | 4 (80.0) | 0 (0.0) |
| ST30, ST33, ST55 | t21 (1) | 0 (0.0) | 1 (100.0) | 0 (0.0) | 0 (0.0) | |
| CC45 | ST45 | t939 (13), t157 (1), t4454 (5) | 1 (5.3) | 1 (5.3) | 3 (15.8) | 1 (5.3) |
| CC508 | ST508 | t15727 (1), t1510 (1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (100.0) |
| CC5 | ST5 | t450 (1) | 0 (0.0) | 1 (100.0) | 0 (0.0) | 0 (0.0) |
| CC707 | ST707 | t15728 (1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (100.0) |
| CC8 | ST8 | t8 (3), t1476 (1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| ST18 | t451 (1) | 0 (0.0) | 1 (100.0) | 1 (100.0) | 0 (0.0) | |
| CC88 | ST88 | t186 (1), t4104 (2) | 0 (0.0) | 0 (0.0) | 3 (100.0) | 0 (0.0) |
| singleton | ST3248 | t6063 (2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (100.0) |
| singleton | ST944 | t616 (2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
CC: Clonal Complex; ST: Sequence Type; MRSA: Methicillin-resistant Staphylococcus aureus; MDR: Multidrug resistant; PVL: Panton-Valentine leukocidin; TSST: Toxic shock syndrome toxin.